查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085139

生物相似單株抗體市場：依抗體類別、分子類別、劑型、治療類型、治療領域和最終用戶分類－2026-2032年全球市場預測

Biosimilar Monoclonal Antibodies Market by Antibody Class, Molecule Class, Dosage Form, Treatment Type, Therapeutic Area, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，生物類似單株抗體市場將成長至 190.5 億美元，複合年成長率為 11.49%。

主要市場統計數據
基準年 2025 88.9億美元
預計年份：2026年 99.1億美元
預測年份 2032 190.5億美元
複合年成長率 (%) 11.49%

生物相似藥單株抗體市場執行摘要

生物類似單株抗體正從降低成本的選擇轉變為支持腫瘤、免疫、眼科和發炎性疾病領域生物製藥療法可及性的核心支柱。這些產品需經過嚴格的等效性評估流程才能獲得批准，該流程要求提供分析、非臨床、藥物動力學、免疫抗原性和臨床證據，以證明其在安全性、純度和療效方面與參考生物製藥無臨床意義上的差異。

將重塑生物類似單株抗體市場的變革性變化

隨著生物類似單株抗體的應用範圍從最初的Infliximab、曲妥珠單抗、Rituximab和Bevacizumab擴展到更廣泛的免疫學和眼科學領域，競爭格局正在發生結構性轉變。 2023年，多種Adalimumab單抗生物相似藥進入美國市場，這標誌著在藥物可及性方面的一個重要里程碑，再次凸顯了支付方協議、替代性判定、處方藥目錄和分銷策略與監管部門的批准同等重要。

人工智慧對生物相似藥研發的累積影響

人工智慧正透過加速候選物質的表徵、預測關鍵品質屬性、最佳化細胞培養參數以及支援等效性評估，累積生物類似單株抗體的價值鏈。機器學習模型正被擴大用於解讀從糖基化、電荷變化、聚集、結合親和性和功效測定中獲得的高維分析數據，從而有助於在研發早期識別變異性。

全球生物類似單株抗體市場的關鍵區域洞察

亞太地區正崛起為生質類似單株抗體的戰略中心，這得益於中國、印度、韓國和日本的生物製藥生產能力，以及對價格合理的腫瘤、自體免疫疾病和眼科療法日益成長的需求。全部區域的監管改革，包括與國際等效性原則一致的生物相似藥指南，正在提升其可信度，而本地生產政策則有助於確保價格合理性和供應的持續性。

針對東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約市場的關鍵群體特定見解。

在東協市場，隨著癌症治療和免疫學領域對生物製藥的需求不斷成長，可負擔性、管理體制框架和在地化生產夥伴關係正成為優先考慮的因素。該地區各國正日益利用國家醫保覆蓋範圍、醫院競標和技術轉移合作來提高藥物可近性，同時滿足複雜生物製藥的藥物安全監測要求。

對主要生物類似單株抗體市場關鍵國家的深入分析。

美國擁有龐大的商業機遇，主要得益於FDA的批准、可替代生物相似藥的認定、報銷機制、藥品福利管理以及商業性提供者「先買後付」的經濟模式。加拿大繼續透過省級報銷和轉換政策推廣生物相似藥的使用，而墨西哥和巴西則透過公共採購、監管現代化和機構採購來擴大生物製藥的可及性。

為生物類似單株抗體領域的領導者提供的實用建議

產業領導企業應優先考慮與高價值生物製藥專利到期日相符、在製劑和給藥方式上具有明顯差異化以及供應可靠性高的產品系列。商業性成功需要儘早與支付方建立合作關係、提供強力的衛生經濟學證據、開展轉換用藥的宣傳活動、提供透明的免疫抗原性信息，以及建立處方醫生、藥劑師和患者信任的藥物安全監測項目。

基於證據的市場估值調查方法

本執行摘要基於系統的二手研究途徑，參考了公開的監管、臨床、政策和市場進入證據。主要參考文獻包括FDA、EMA、WHO和各國監管機構的生物相似藥指南和核准資料庫、公共採購框架、同行評審文獻、臨床試驗註冊資訊、藥物安全監測資源以及權威的醫療保健政策資訊來源。

結論：生物類似單株抗體正進入大規模的時代。

隨著醫療系統在努力降低成本的同時維持臨床療效，生物類似單株抗體正成為永續生物製藥製藥發展的關鍵要素。市場不再僅僅由核准產品的數量決定，而是越來越受到互通性、合約策略、醫生信任、真實世界數據、藥物安全監測和卓越生產技術等因素的驅動。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：生物相似單株抗體市場：依抗體類別分類

  • 嵌合體單株抗體
  • 人源化單株抗體

第8章：生物相似單株抗體市場：依分子類別分類

  • Adalimumab
  • Infliximab
  • Rituximab
  • 曲妥珠單抗
  • Bevacizumab
  • 雷尼珠單抗

第9章：生物相似單株抗體市場：依劑型分類

  • 液體
  • 凍乾粉
  • 預填充式注射器

第10章：生物類似單株抗體市場：依治療類型分類

  • 單藥治療
  • 聯合治療

第11章：生物類似單株抗體市場：依治療領域分類

  • 免疫學
  • 腫瘤學
  • 眼科
  • 風濕病學
  • 自體免疫/發炎性疾病

第12章：生物類似單株抗體市場：依最終用戶分類

  • 專科診所
  • 醫院
  • 家庭醫療保健

第13章：生物類似單株抗體市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：生物類似單株抗體市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：生物類似單株抗體市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Alvotech hf
  • Amgen Inc.
  • Aurobindo Pharma Ltd.
  • Bio-Thera Solutions, Ltd.
  • Biocon Ltd.
  • Boehringer Ingelheim International GmbH
  • Celltrion, Inc.
  • Coherus BioSciences, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Formycon AG
  • Fresenius Kabi AG
  • Intas Pharmaceuticals Ltd.
  • Lupin Ltd.
  • Mabwell Bioscience
  • Merck KGaA
  • Pfizer Inc.
  • Polpharma Biologics Group
  • Qilu Pharmaceutical Co., Ltd.
  • Reliance Life Sciences
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Shanghai Henlius Biotech, Inc.
  • Stada Arzneimittel AG
Product Code: MRR-437D45957E9F

The Biosimilar Monoclonal Antibodies Market is projected to grow by USD 19.05 billion at a CAGR of 11.49% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.89 billion
Estimated Year [2026] USD 9.91 billion
Forecast Year [2032] USD 19.05 billion
CAGR (%) 11.49%

Biosimilar Monoclonal Antibodies Market Executive Summary

Biosimilar monoclonal antibodies are moving from a cost-containment option to a core pillar of biologic therapy access across oncology, immunology, ophthalmology, and inflammatory diseases. These products are approved through rigorous comparability pathways requiring analytical, nonclinical, pharmacokinetic, immunogenicity, and clinical evidence showing no clinically meaningful differences from reference biologics in safety, purity, and potency.

The market is shaped by patent expirations for high-revenue biologics, increasing payer pressure, and expanding physician confidence as real-world evidence accumulates. Regulatory precedents from the FDA, EMA, WHO, and national agencies have strengthened trust in biosimilar monoclonal antibodies, while hospital formularies and specialty pharmacy channels are accelerating adoption where procurement systems reward value-based competition.

Transformative Shifts Reshaping Biosimilar Monoclonal Antibodies

The competitive landscape is undergoing a structural shift as biosimilar monoclonal antibodies expand beyond early infliximab, trastuzumab, rituximab, and bevacizumab categories into broader immunology and ophthalmology opportunities. The U.S. entry of multiple adalimumab biosimilars in 2023 marked a pivotal access milestone, reinforcing that payer contracting, interchangeability decisions, formulary placement, and channel strategy can be as important as regulatory approval.

Manufacturers are responding with more efficient cell-line development, advanced analytics, high-concentration formulations, citrate-free presentations, and device differentiation. At the same time, health systems are tightening evidence expectations around switching, extrapolation of indications, immunogenicity, pharmacovigilance, and supply reliability, making manufacturing quality and post-market data central competitive differentiators.

Cumulative Impact of Artificial Intelligence on Biosimilar Development

Artificial intelligence is cumulatively improving the biosimilar monoclonal antibody value chain by accelerating candidate characterization, predicting critical quality attributes, optimizing cell-culture parameters, and supporting comparability assessments. Machine learning models are increasingly used to interpret high-dimensional analytical data from glycosylation, charge variants, aggregation, binding affinity, and potency assays, helping teams identify variability earlier in development.

AI also supports regulatory intelligence, pharmacovigilance signal detection, literature surveillance, demand planning, and market access strategy. However, adoption remains bounded by validation, data integrity, model explainability, cybersecurity, and regulatory documentation requirements. The most credible near-term impact is not replacing biosimilar evidence generation, but reducing development risk, improving manufacturing consistency, and strengthening post-launch monitoring.

Key Regional Insights Across Global Biosimilar Monoclonal Antibody Markets

Asia-Pacific is emerging as a strategic biosimilar monoclonal antibodies hub, supported by biologics manufacturing capacity in China, India, South Korea, and Japan, along with rising demand for affordable oncology, autoimmune, and ophthalmology therapies. Regulatory reforms across the region, including biosimilar guidelines aligned with international comparability principles, are improving confidence while local production policies help address affordability and supply continuity.

North America remains highly influenced by payer contracting, FDA biosimilar and interchangeable designations, reimbursement design, and specialty pharmacy dynamics, with the United States driving commercial complexity and Canada emphasizing provincial switching policies. Latin America is advancing through procurement-led access models, reliance pathways, and regulatory convergence, with Brazil and Mexico playing important roles in public health purchasing and biosimilar policy development.

Europe remains the most mature adoption environment, supported by EMA experience, national tendering systems, physician familiarity with biosimilar switching, and extensive real-world evidence in immunology and oncology. The Middle East, especially GCC markets, is expanding biologics access through public-sector investment, hospital modernization, and national health transformation programs, while Africa shows long-term potential where cold-chain infrastructure, pricing, local regulatory capacity, and procurement financing continue to shape uptake.

Key Group Insights for ASEAN, GCC, EU, BRICS, G7, and NATO Markets

ASEAN markets are prioritizing affordability, regulatory capacity building, and local manufacturing partnerships as demand rises for oncology and immunology biologics. Countries in the region are increasingly using national reimbursement lists, hospital tenders, and technology transfer collaborations to improve access while maintaining pharmacovigilance requirements for complex biologics.

The GCC is using centralized purchasing, hospital modernization, and national health transformation programs to expand biosimilar access, particularly in Saudi Arabia and the United Arab Emirates. The European Union remains the benchmark for biosimilar policy maturity, with centralized EMA evaluation, national substitution or switching frameworks, and country-level tendering driving competition and physician acceptance.

BRICS economies are strategically important because China, India, Brazil, and Russia combine large patient populations with domestic biologics ambitions, while South Africa's access priorities highlight the need for affordability and reliable supply. G7 markets offer strong regulatory predictability and reimbursement sophistication, and NATO members in Europe and North America are increasingly focused on medicine supply resilience, biologic affordability, and secure pharmaceutical manufacturing networks.

Key Country Insights in Major Biosimilar Monoclonal Antibody Markets

The United States is a major commercial opportunity shaped by FDA approvals, interchangeable biosimilar designations, reimbursement design, pharmacy benefit management, and provider-administered buy-and-bill economics. Canada continues to promote biosimilar use through provincial reimbursement and switching policies, while Mexico and Brazil use public procurement, regulatory modernization, and institutional purchasing to broaden biologic access.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from established biosimilar prescribing experience, although tendering, physician autonomy, substitution policy, and payer incentives vary by country. Russia has emphasized domestic biologics production and import substitution policies, while China and India combine large treatment-naive populations with expanding biosimilar manufacturing capacity, improving access to monoclonal antibody therapies across oncology and inflammatory diseases.

Japan maintains stringent regulatory standards and a cautious but evidence-based adoption environment, while South Korea is recognized as a major global biosimilar manufacturing base supported by advanced biologics infrastructure and regulatory experience. Australia supports uptake through reimbursement policy, reference pricing mechanisms, and clinician education, making it an important developed Asia-Pacific market for evidence-based biosimilar adoption.

Actionable Recommendations for Biosimilar Monoclonal Antibody Leaders

Industry leaders should prioritize portfolios aligned with high-value biologic patent expirations, clear differentiation in formulation or delivery, and strong supply reliability. Commercial success requires early payer engagement, robust health economic evidence, switching education, transparent immunogenicity communication, and pharmacovigilance programs that build confidence among prescribers, pharmacists, and patients.

Organizations should invest in advanced analytics, quality-by-design manufacturing, and real-world evidence platforms to demonstrate consistency beyond approval. Partnerships with hospitals, specialty pharmacies, government procurement agencies, and local manufacturers can improve market entry, particularly in price-sensitive regions where tender performance, cold-chain readiness, and access commitments determine scale.

Research Methodology for Evidence-Based Market Assessment

This executive summary is developed using a structured secondary research approach grounded in publicly available regulatory, clinical, policy, and market-access evidence. Core references include biosimilar guidance and approval databases from the FDA, EMA, WHO, national regulatory authorities, public procurement frameworks, peer-reviewed literature, clinical trial registries, pharmacovigilance resources, and recognized healthcare policy sources.

The methodology emphasizes triangulation across regulatory approvals, patent and exclusivity events, payer policy trends, therapeutic adoption patterns, switching guidance, and manufacturing capabilities. Insights were assessed for relevance to monoclonal antibody biosimilars, with preference for verifiable evidence over promotional claims and a focus on commercially actionable trends without relying on market sizing, market share, or forecasting assumptions.

Conclusion: Biosimilar Monoclonal Antibodies Enter a Scaled Access Era

Biosimilar monoclonal antibodies are becoming essential to sustainable biologic care as health systems seek to reduce costs while preserving clinical outcomes. The market is no longer defined only by approval counts; it is increasingly driven by interchangeability, contracting strategy, physician confidence, real-world evidence, pharmacovigilance, and manufacturing excellence.

Organizations that combine scientific rigor with agile market access execution will be best positioned to strengthen adoption. As AI-enabled analytics, regulatory maturity, and global procurement reforms advance, biosimilar monoclonal antibodies are expected to play a larger role in expanding patient access to high-value biologic therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Biosimilar Monoclonal Antibodies Market, by Antibody Class

  • 7.1. Chimeric Monoclonal Antibodies
  • 7.2. Humanized Monoclonal Antibodies

8. Biosimilar Monoclonal Antibodies Market, by Molecule Class

  • 8.1. Adalimumab
  • 8.2. Infliximab
  • 8.3. Rituximab
  • 8.4. Trastuzumab
  • 8.5. Bevacizumab
  • 8.6. Ranibizumab

9. Biosimilar Monoclonal Antibodies Market, by Dosage Form

  • 9.1. Liquid Solution
  • 9.2. Lyophilized Powder
  • 9.3. Prefilled Syringe

10. Biosimilar Monoclonal Antibodies Market, by Treatment Type

  • 10.1. Monotherapy
  • 10.2. Combination Therapy

11. Biosimilar Monoclonal Antibodies Market, by Therapeutic Area

  • 11.1. Immunology
  • 11.2. Oncology
  • 11.3. Ophthalmology
  • 11.4. Rheumatology
  • 11.5. Autoimmune & Inflammatory Diseases

12. Biosimilar Monoclonal Antibodies Market, by End User

  • 12.1. Specialty Clinics
  • 12.2. Hospitals
  • 12.3. Home Healthcare

13. Biosimilar Monoclonal Antibodies Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Biosimilar Monoclonal Antibodies Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biosimilar Monoclonal Antibodies Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Alvotech hf
  • 17.2. Amgen Inc.
  • 17.3. Aurobindo Pharma Ltd.
  • 17.4. Bio-Thera Solutions, Ltd.
  • 17.5. Biocon Ltd.
  • 17.6. Boehringer Ingelheim International GmbH
  • 17.7. Celltrion, Inc.
  • 17.8. Coherus BioSciences, Inc.
  • 17.9. Dr. Reddy's Laboratories Ltd.
  • 17.10. Formycon AG
  • 17.11. Fresenius Kabi AG
  • 17.12. Intas Pharmaceuticals Ltd.
  • 17.13. Lupin Ltd.
  • 17.14. Mabwell Bioscience
  • 17.15. Merck KGaA
  • 17.16. Pfizer Inc.
  • 17.17. Polpharma Biologics Group
  • 17.18. Qilu Pharmaceutical Co., Ltd.
  • 17.19. Reliance Life Sciences
  • 17.20. Samsung Bioepis Co., Ltd.
  • 17.21. Sandoz International GmbH
  • 17.22. Shanghai Henlius Biotech, Inc.
  • 17.23. Stada Arzneimittel AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHIMERIC MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHIMERIC MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHIMERIC MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HUMANIZED MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMANIZED MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HUMANIZED MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ADALIMUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ADALIMUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ADALIMUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFLIXIMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INFLIXIMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFLIXIMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RITUXIMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RITUXIMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RITUXIMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRASTUZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TRASTUZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRASTUZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BEVACIZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BEVACIZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BEVACIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RANIBIZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RANIBIZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RANIBIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LIQUID SOLUTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LIQUID SOLUTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LIQUID SOLUTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PREFILLED SYRINGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PREFILLED SYRINGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PREFILLED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMMUNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMMUNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMMUNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RHEUMATOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RHEUMATOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RHEUMATOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AUTOIMMUNE & INFLAMMATORY DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AUTOIMMUNE & INFLAMMATORY DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AUTOIMMUNE & INFLAMMATORY DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. GCC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 123. GCC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. GCC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
  • TABLE 125. GCC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 126. GCC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. GCC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 128. GCC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. G7 BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. G7 BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
  • TABLE 145. G7 BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. G7 BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 147. G7 BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. G7 BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 149. G7 BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. NATO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 151. NATO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. NATO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
  • TABLE 153. NATO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 154. NATO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. NATO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 156. NATO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 166. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
  • TABLE 167. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
  • TABLE 168. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 169. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 171. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
  • TABLE 175. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 176. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 178. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
  • TABLE 181. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
  • TABLE 182. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 183. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 185. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
  • TABLE 195. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
  • TABLE 196. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 197. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 199. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 201. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
  • TABLE 202. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
  • TABLE 203. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 204. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 206. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
  • TABLE 209. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
  • TABLE 210. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 211. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 213. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
  • TABLE 216. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
  • TABLE 217. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 218. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 220. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
  • TABLE 223. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
  • TABLE 224. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 225. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 227. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
  • TABLE 237. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
  • TABLE 238. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 239. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 241. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
  • TABLE 244. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
  • TABLE 245. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 246. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 248. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
  • TABLE 251. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
  • TABLE 252. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 253. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 255. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
  • TABLE 258. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
  • TABLE 259. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 260. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 262. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)